Jay Chappell, MD
Cardiovascular Disease · Springfield, ORNPI 1659379824
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,922 of the $11,869 with a category attached, or 66.7%. Abbott accounts for 76.4% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2024 at $2,998 and has fallen 79.8% since, to $607 in 2025.
Across 198 payments — averaging $59.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$9K
- Edwards Lifesciences$574
- Medtronic$438
- Novartis$416
- AstraZeneca$142
- Regeneron Healthcare Solutions, Inc.$128
- plus $1K from 18 others
What the payments were for
- Consulting fees$7,92267%
- Food & beverage$3,83332%
- Education$1141%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 75 | $9,065 |
| Edwards Lifesciences | 7 | $574 |
| Medtronic(2 entities) | 8 | $438 |
| Novartis | 31 | $416 |
| AstraZeneca | 9 | $142 |
| Regeneron Healthcare Solutions, Inc. | 9 | $128 |
| E.r. Squibb & Sons, L.L.C. | 8 | $126 |
| Pfizer | 8 | $110 |
| Inari Medical, Inc. | 1 | $99 |
| Amgen | 5 | $98 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $93 |
| Abiomed | 3 | $79 |
| Bristol Myers Squibb | 4 | $71 |
| Amarin Pharma, Inc. | 2 | $71 |
| Johnson & Johnson | 4 | $56 |
| Exact Sciences | 2 | $51 |
| Boehringer Ingelheim | 2 | $49 |
| Irhythm Technologies, Inc. | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $36 |
| Alnylam Pharmaceuticals Inc. | 2 | $30 |
| Sanofi-aventis U.S. LLC | 2 | $28 |
| Shockwave Medical, Inc | 1 | $28 |
| Medicomp Inc | 1 | $24 |
| Novo Nordisk | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACCENT$2,933
- Endurity Pacemaker$1,692
- Allure CRT Pacemaker$1,551
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$1,000
- Accent Pacemaker$746
- SAPIEN 3 Ultra RESILIA$284
- CoreValve Evolut$232
- AVEIR$166
- ASSURITY$136
- Edwards SAPIEN 3 Transcatheter Heart Valve$109
How this compares
$11,869 in reported general payments places this provider in the 85th percentile of 198 cardiovascular disease providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 889 | $1,224,822 |
| FarxigaDapagliflozin Propanediol | 38 | $39,250 |
| Repatha SureclickEvolocumab | 25 | $33,257 |
| JardianceEmpagliflozin | 27 | $25,189 |
| XareltoRivaroxaban | 11 | $14,500 |
| Rosuvastatin Calcium | 712 | $11,325 |
| Valsartan | 245 | $8,527 |
| Nebivolol Hcl | 141 | $7,813 |
| Metoprolol Succinate | 439 | $7,182 |
| Flecainide Acetate | 148 | $5,643 |
| Telmisartan | 205 | $5,285 |
| Ezetimibe | 239 | $5,047 |
| Torsemide | 248 | $5,020 |
| Carvedilol | 390 | $4,709 |
| Atorvastatin Calcium | 279 | $4,491 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $110 | $1,224,822889 claims |
| AstraZenecaFarxiga | $142 | $39,25038 claims |
| Boehringer IngelheimJardiance | $49 | $25,18927 claims |
| Johnson & JohnsonXarelto | $56 | $14,50011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 198 cardiovascular disease providers in Oregon.
Other cardiovascular disease in Springfield
- Sreekanth KaranamSpringfield$37K
- Matthew TrojanSpringfield$22K
- Richard PadgettSpringfield$5K
- Joseph ThouinSpringfield$5K
- Ling JinSpringfield$4K
- Sushan SweeneySpringfield$3K
- Firas ZahrPortland$810K
- Kathy GreweHood River$376K
- Scott ChadderdonPortland$282K
- Ahmad MasriPortland$227K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.